Table 2.

Reason for progression (using RECIST criteria of 20% for target tumors) in each treatment group

PFS events (20% cutoff)ExperimentalControlTotal
Deaths437361798
Progression typea2,3281,7154,043
Target tumor1,194 (51%)902 (53%)2,096 (52%)
Nontarget tumor235 (10%)190 (11%)425 (11%)
New lesion676(29%)436 (25%)1,112 (28%)
New lesion and nontarget223 (10%)187 (11%)410 (10%)
  • aFollow-up postprogression was different in the treatment and control arms.